# Golcadomide

Source: https://onco.cc/drugs/golcadomide/  
OnCo record `golcadomide` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Golcadomide is a next-generation lenalidomide-like pill that degrades two lymphoma transcription factors far more potently, now in phase 3 with R-CHOP.

## Summary

Golcadomide is a cereblon E3 ligase modulator (CELMoD): it binds cereblon and recruits the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) for ubiquitination and proteasomal degradation, which downregulates IRF4 and MYC in lymphoma cells and stimulates T cells, far more potently than lenalidomide. In phase 1/2, golcadomide with rituximab gave an ORR of about 50% in relapsed or refractory DLBCL, and with R-CHOP in untreated high-risk DLBCL it produced high complete response rates (ASH 2024). The phase 3 GOLSEEK-1 trial is enrolling patients with IPI 3 to 5 disease to compare golcadomide plus R-CHOP with R-CHOP alone, with readout expected in 2027 to 2028. BMS develops it. It is a next-generation lenalidomide-like pill designed to be added to standard first-line chemotherapy.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-07
- Code: CC-99282, BMS-986369
- Modality: Molecular glue degrader (CELMoD, IKZF1/3)
- Mechanism: Binds cereblon and recruits IKZF1/IKZF3 for ubiquitination and proteasomal degradation; downregulates IRF4/MYC and stimulates T cells.

## Sources

- ClinicalTrials.gov NCT06356129 (GOLSEEK-1): https://clinicaltrials.gov/study/NCT06356129

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- technologies: [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [IKZF1 (Ikaros)](https://onco.cc/targets/ikzf1/), [IKZF3 (Aiolos)](https://onco.cc/targets/ikzf3/), [IRF4](https://onco.cc/targets/irf4/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- trials: [A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)](https://onco.cc/trials/nct06835530/), [A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No](https://onco.cc/trials/nct03930953/), [A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas](https://onco.cc/trials/nct06090539/), [A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela](https://onco.cc/trials/nct06911502/), [A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma](https://onco.cc/trials/nct06425302/), [GOLSEEK-1](https://onco.cc/trials/golseek-1/)
- pathways: [Ubiquitin-proteasome system & protein homeostasis](https://onco.cc/pathways/ubiquitin-proteasome-system/)
- roadmaps: [Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome](https://onco.cc/roadmaps/epigenetics-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/golcadomide.json